ArticleFrontiers in pediatrics2026
Ischemia-modified albumin in children with clinically suspected acute myocarditis: diagnostic performance and incremental value beyond conventional biomarkers.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Predictors of Hospital Admission and Cardiac Diagnosis in Children Presenting with Chest Pain: The Role of Recurrent Presentation and Inflammatory Markers.Medicina (Kaunas, Lithuania) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pediatric acute myocarditis is challenging because presentations range from chest pain to cardiogenic shock, and no single biomarker reflects its inflammatory, ischemic, and hemodynamic components. Ischemia-modified albumin (IMA), a marker of oxidative stress-related alteration in albumin measured by the albumin cobalt-binding assay, has been investigated in ischemic and inflammatory conditions, but its role in pediatric myocarditis remains unclear. Methods: In this prospective, single-center case-control study, 47 children with clinically suspected acute myocarditis and 47 age- and sex-matched healthy controls were evaluated between 1 July 2023 and 1 July 2025. Clinically suspected acute myocarditis was defined according to pediatric guidance as at least one compatible clinical feature together with at least one supportive biomarker, electrocardiographic, or echocardiographic finding after exclusion of alternative diagnoses. IMA levels were measured using the albumin cobalt-binding method and expressed as absorbance units (ABSU). The statistical analysis included between-group comparisons, receiver operating characteristic (ROC) analyses, incremental discrimination analyses, and exploratory clinical severity analyses. Results: IMA concentrations were significantly higher in the myocarditis group than in controls [0.57 (0.55-0.63) vs. 0.55 (0.49-0.59) ABSU, Conclusion: IMA is elevated in children with clinically suspected acute myocarditis, but its standalone diagnostic performance is limited and its added value beyond conventional biomarkers appears small. IMA may be considered an adjunctive rather than a primary diagnostic biomarker, and any putative triage role in ultra-early presentations remains hypothesis-generating.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.